Organogenesis (NASDAQ:ORGO) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Organogenesis (NASDAQ:ORGO) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. UBS Group set a $3.00 target price on Organogenesis in a report on Thursday, May 28th. Weiss Ratings lowered shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 4th. Finally, Truist Financial reduced their price target on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $4.33.

Organogenesis Stock Up 4.4%

Shares of NASDAQ ORGO opened at $1.42 on Friday. The stock has a market capitalization of $182.73 million, a PE ratio of -1.65 and a beta of 1.29. The company has a quick ratio of 3.00, a current ratio of 3.52 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average of $1.98 and a 200-day moving average of $2.30. Organogenesis has a 52-week low of $1.34 and a 52-week high of $7.08.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). The firm had revenue of $43.76 million during the quarter, compared to analysts’ expectations of $54.27 million. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.

Institutional Investors Weigh In On Organogenesis

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Organogenesis during the 2nd quarter valued at about $17,616,000. Dimensional Fund Advisors LP boosted its holdings in Organogenesis by 5.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock worth $6,851,000 after acquiring an additional 160,026 shares during the period. Deutsche Bank AG purchased a new position in Organogenesis in the 2nd quarter worth approximately $4,146,000. Renaissance Technologies LLC grew its position in Organogenesis by 30.5% in the first quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company’s stock valued at $2,532,000 after acquiring an additional 249,838 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Organogenesis by 39.8% in the first quarter. SG Americas Securities LLC now owns 790,766 shares of the company’s stock valued at $1,874,000 after acquiring an additional 225,265 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company focused on regenerative medicine products for wound care, surgical procedures and sports medicine. The company develops and commercializes biologically derived products designed to support tissue repair and healing.

Its advanced wound care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as products such as Dermagraft, Affinity, NuShield and other wound coverings and tissue matrices.